Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Monday the receipt of the final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Imatinib Mesylate Tablets in 100mg and 400mg product strengths.
The company added that the ANDA for Imatinib Mesylate Tablets was developed in collaboration with Stason Pharmaceuticals Inc and is the generic version for Gleevec Tablets by Novartis. The Imatinib Mesylate Tablets product will be commercially manufactured by Stason in 100mg and 400mg product strengths.
In conjunction with the US FDA approval, Breckenridge said it plans to launch the product in the near future.
For the year ending 31 December 2018, the Gleevec Tablets generated annual sales of approximately USD654.8m, according to industry sales data.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules